Company Profile

AADI LLC
Profile last edited on: 3/16/2021            CAGE: 6LMB3

MTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases
Year Founded
2011
1st Award Year
2012
Latest Award
2015
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

16730 Calle De Catalina
Pacific Palisades, CA 90272
   (310) 309-9036
   N/A
   aadibio.com
Multiple Locations:   
Congressional District:   33
County:   Los Angeles

Public Profile

AADi, LLC, - also dba as AADI Biosciences - is a clinical stage biopharmaceutical company structured around in-house invented, lead product TARZIFYX™ - sirolimus albumin-bound nanoparticles for injectable suspension, ABI-009 -- mTOR inhibitor complexed with human albumin that has significantly higher tumor accumulation and improved efficacy over other mTOR inhibitors in preclinical models. With mTOR as a therapeutic target well recognized in oncology, Aadi is focused on developing the full potential of albumin-bound sirolimus in therapeutic areas and diseases that are driven by mTOR activation and where the mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety or effective targeting to the disease site. These indications include oncology, cardiovascular, CNS, mitochondrial disease and diseases of ageing.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2015 2 NIH $1,565,974
Investigation of a Nanoparticle Albumin-Bound Mtor Inhibitor, Nab-Rapamycin for T

Key People / Management

  Neil Desai -- Founder, CEO and President

  Mitchall Clark -- Regulatory Affairs and Quality Advisor SVP, Regulatory Affairs and Quality Assur

  Berta Grigorian -- VP Clinical Operations

  Madhu Kalaimalai --